載入...
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
BACKGROUND: Anti-EGFR antibody–based treatment is an important therapeutic strategy for advanced colorectal cancer (CRC); despite this, several mutations—including KRAS, BRAF, and PIK3CA mutations, and HER2 amplification—are associated with the mechanisms underlying the development of resistance to...
Na minha lista:
| 發表在: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4798471/ https://ncbi.nlm.nih.gov/pubmed/26991109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0151865 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|